Ligand id: 6786

Name: aflibercept

No information available.
Summary of Clinical Use
Aflibercept is used in the treatment of macular edema following central retinal vein occlusion (CRVO), diabetic macular edema and neovascular age-related macular degeneration (AMD, wet macular degeneration). In 2015 the FDA expanded the approved use of aflibercept to include the treatment of diabetic retinopathy in patients with diabetic macular edema. The Zaltrap® brand is used to treat metastatic colorectal cancer.
Mechanism Of Action and Pharmacodynamic Effects
Alfibercept binds with high affinity to vascular endothelial growth factor (VEGF-A and -B) and placenta growth factor (PIGF-1 and -2), thereby inhibiting the neovascularization and vascular permeability actions of these peptides. This results in antitumour effects.
External links